Mushroom supplement may slow prostate cancer progression, City of Hope study finds

Insights from ASCO 2025: Real-world evidence drives clinical decision-making

City of Hope researchers presented compelling real-world evidence and novel combination therapies at the 2025 ASCO Annual Meeting, with findings that could reshape treatment approaches for breast, colorectal, renal, and prostate cancers.

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats

For more than a year before her stage 4 lung cancer was found, 35-year-old Alisa Secaida, a never-smoker and a physically active Southern Californian, had been experiencing a persistent cough and, increasingly, fatigue.

June 06, 2025

Vol.51 No.22

By Claire Marie Porter

Reimagining cancer care for a new generation of patients

The landscape of cancer is shifting beneath our feet, and we must adapt our clinical practice accordingly.

S2302 Pragmatica-Lung reports out as model for faster, leaner, more representative trials

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary question, finding that the investigational combination it tested did not significantly extend overall survival compared to standard of care treatments.

June 06, 2025

Vol.51 No.22

Clinical Roundup

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

First-line treatment with the triplet combination of encorafenib, cetuximab, and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the phase III BREAKWATER trial led by researchers from the University of Texas MD Anderson Cancer Center.

June 06, 2025

Vol.51 No.22

Clinical Roundup

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer improved long-term survival overall compared with chemotherapy alone, according to a clinical trial published June 2 in The New England Journal of Medicine and presented at the annual meeting of the American Society of Clinical Oncology.

June 06, 2025

Vol.51 No.22

Mushroom supplement may slow prostate cancer progression, City of Hope study finds

YOU MAY BE INTERESTED IN

Insights from ASCO 2025: Real-world evidence drives clinical decision-making

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats

Reimagining cancer care for a new generation of patients

S2302 Pragmatica-Lung reports out as model for faster, leaner, more representative trials

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login

Mushroom supplement may slow prostate cancer progression, City of Hope study finds

YOU MAY BE INTERESTED IN

Insights from ASCO 2025: Real-world evidence drives clinical decision-making

Young women are now diagnosed with cancer at twice the rate of young menThe face of cancer is changing at a time when research is plagued by existential threats

Reimagining cancer care for a new generation of patients

S2302 Pragmatica-Lung reports out as model for faster, leaner, more representative trials

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

Neoadjuvant immunotherapy + chemo regimen significantly improves long-term survival in NSCLC

Never miss an issue!

Login

Young women are now diagnosed with cancer at twice the rate of young men
The face of cancer is changing at a time when research is plagued by existential threats